CrossMark dick for updates

# G OPEN ACCESS

**Citation:** Zhang W, Qu H-C, Yu M, Zhang Y (2015) The Effects of Maxillary Protraction with or without Rapid Maxillary Expansion and Age Factors in Treating Class III Malocclusion: A Meta-Analysis. PLoS ONE 10(6): e0130096. doi:10.1371/journal. pone.0130096

Academic Editor: Cristina Teixeira, New York University, UNITED STATES

Received: January 19, 2015

Accepted: May 15, 2015

Published: June 11, 2015

**Copyright:** © 2015 Zhang et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** The authors have no support or funding to report.

**Competing Interests:** The authors have declared that no competing interests exist.

**RESEARCH ARTICLE** 

# The Effects of Maxillary Protraction with or without Rapid Maxillary Expansion and Age Factors in Treating Class III Malocclusion: A Meta-Analysis

#### Wei Zhang<sup>1</sup>, Hong-Chen Qu<sup>2</sup>, Mo Yu<sup>1</sup>, Yang Zhang<sup>1</sup>\*

1 Department of Orthodontics, School of Stomatology, China Medical University, Shenyang, Liaoning, P.R. China, 2 Department of Urological Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, P.R. China

\* zgykdxzhangyang@126.com

# Abstract

We conducted a comprehensive meta-analysis of 12 studies to examine whether maxillary protraction face mask associated with rapid maxillary expansion (FM/RME) could be an effective treatment for Class III malocclusion and to evaluate the effect of timing on treatment response. Patients with a maxillary deficiency who were treated with FM with or without RME were compared with those who had an untreated Class III malocclusion. In both treatment groups, forward displacement of the maxilla and skeletal changes were found to be statistically significant. In addition, posterior rotation of the mandible and increased facial height were more evident in the FM group compared with the control group. However, no significant differences were observed between the early treatment groups and late treatment groups. The results indicated that both FM/RME and FM therapy produced favorable skeletal changes for correcting anterior crossbite, and the curative time was not affected by the presence of deciduous teeth, early mixed dentition or late mixed dentition in the patient.

### Introduction

Mandibular or mandibular dentition prognathism, retrusive maxillary or maxillary dentition, and combinations of these components may lead to a Class III malocclusion [1-5]. According to surveys, seventy-five percent of skeletal Class III malocclusions are caused by maxillary retrognathism or a combination of maxillary retrognathism and mandibular prognathism. Several authors have agreed that maxillary retrusion is the most common contributing component of Class III features [5,6]. Because the possibility of Class III malocclusion characterized by maxillary hypoplasia should be considered, it has become more important to use devices that encourage maxillary growth. Several techniques have been described to effectively protract the maxilla, including the use of a face mask (FM) or reverse chin cup and the application of direct force via ankylosed primary canines [7-13]. In addition, miniplate and miniscrew implants

have also been used to provide the necessary orthodontic anchorage in patients with retrusive maxillary dentition[14–19]. The treatment of a skeletal Class III malocclusion is challenging for orthodontics, primarily because of the concave profile of the midface and the unpredictable growth potential of the maxilla coupled with potentially unfavorable mandibular growth.

Current non-surgical treatment methods for severe skeletal Class III malocclusions to correct maxillary discrepancies in young adolescents include rapid maxillary expansion (RME) [20-23]. However, maxillary advancement through the application of extra-oral orthopedic force is considered a viable treatment option in developing children. As a result, FM protraction therapy also has been advocated during the early treatment of Class III malocclusion with maxillary deficiency. A FM is a device commonly used to interfere with growing class III malocclusions with maxillary deficiency, and the use of FM to encourage maxilla growth has gained popularity among orthodontists over the last 30 years. However, the real skeletal encouragement of maxilla growth over time from this traditional method has been debated and remains controversial. Most skeletal Class III malocclusions include disharmony in terms of the length and width of the maxilla, which can be corrected by a rapid maxilla expander. Therefore, we want to provide the best evidence and further persuasive data to confirm the validity of FM and to determine whether the combination of FM/RME is an effective method to improve anterior crossbite. This systematic literature review was also conducted to determine whether an early treatment time is the optimal period to begin FM treatment because an earlier treatment start might lead to more growth compared with that of late controls.

#### **Materials and Methods**

#### 1 Literature search

We used ['face mask' or 'FM'], ['face mask/rapid maxillary expansion' or 'FM/RME' (text word)], [Class III malocclusion or Angle Class III (MeSH)] and ['maxillary protractor'] as search terms. The wide electronic search scope included PubMed, Cochrane Library, Web of Science, Springer Link, and ScienceDirect. In addition, we searched all these databases to avoid missing relevant studies published before October 6, 2014. We also evaluated studies that were cited in the reference lists of the included papers to ensure the inclusion of all relevant studies.

### 2 Inclusion and exclusion criteria

The publications had to reach the following standards to meet the strict inclusive criteria: i) the study concentrated on the treatment efficacy of FM or FM/RME and the relationship between timing factors and maxillary protraction; ii) all patients had clinical Class III malocclusion from the period of early mixed dentition to early permanent dentition, and their ages ranged from seven to fourteen years old; iii) the study provided the original data, or we were able to obtain the data from the primary data; and iv) the study was a case-control study or a randomized controlled trial (RCT). Moreover, the language of all included studies had to be English. We required complete, accurate, and useful data; consequently, reviews, abstracts, conference papers, case reports and letters were excluded without consideration.

#### 3 Data extraction

We extracted information from the included research, such as author names, publication year, volume and issue; article design; number of cases and placebos, efficacy and safety assessment. Wei Zhang and Hong-Chen Qu independently checked the data from all the included studies. Subsequently, a third reviewer (Yang Zhang) discussed inconsistent evaluations and thereby helped to reach a final agreement.

### 4 Quality assessment of the included studies

Each publication's quality was assessed by two reviewers (Wei Zhang and Hong-Chen Qu) according to a modified STROBE quality score system [24, 25]. The quality-assessment scores ranged from 0 to 44. Scores of 0-17.5 were regarded as poor, 7.5–35 as fair, and 35–44 as good. Subsequently, the two reviewers met to discuss disagreements and draw a final reasonable conclusion.

### 5 Statistical analysis

To acquire reliable and accurate results, two authors (Mo Yu and Yang Zhang) who were not involved in the data collection were in charge of extracting the data. The authors calculated the mean difference (MD) and 95% CI using Review Manager Version 5.3 software (provided by the Cochrane Collaboration). The I<sup>2</sup> test was used to quantify the effect of heterogeneity. A higher result on the I<sup>2</sup> test represented an increased possibility that heterogeneity contributed to the inter-study variability. Both fixed-effects and random-effects models were used: if the I<sup>2</sup> test < 50% or P  $\geq$  0.05 (Q-test), we used the fixed-effects model; if there was significant heterogeneity among the included studies (I<sup>2</sup> test > 50%), the random-effects model was employed. We used Funnel plots to detect publication bias; a symmetrical plot indicated little publication bias.

## Results

### 1 Characteristics of the included studies

Based on the inclusion criteria, we included 12 satisfactory studies[26–37] in the meta-analysis. Fig 1 shows the flow chart of study selection. The 12 studies included 318 patients with retruded maxilla characterized by Class III malocclusion and 228 untreated Class III malocclusion control patients. The studies included were published from 1998 to 2014. All treatment groups received the maxilla protractor with or without rapid maxillary expansion. The control patients were defined as having Class III malocclusion using cephalometric angular and linear parameter analysis. The baseline quality score of the involved studies was 17.5 (fair or good). Table 1 illustrates the methodological quality and characteristics of the included studies.

# 2 Differences in FM-treated Class III malocclusion patients group and untreated controls

This meta-analysis demonstrated the difference in FM-treated Class III malocclusion patients and controls (Fig 2). We evaluated the five cephalometric parameters most relevant to anterior crossbite compared with those of controls to identify the therapeutic effect and skeletal changes: SNA (SMD = 1.78, 95% CI = 1.57–1.99, P < 0.00001); SNB (SMD = -1.75, 95% CI = -2.28–-1.23, P < 0.00001); ANB (SMD = 3.64, 95% CI = 3.10–4.19, P < 0.00001); SN/GoGn (SMD = 1.67, 95% CI = 0.63–2.71, P = 0.002); and ANS-Me (SMD = 2.92, 95% CI = 2.61–3.23, P < 0.00001). These results suggest that a maxillary protraction appliance can effectively correct anterior crossbite with a retruded maxilla. After FM therapy, the maxilla was displaced anteriorly, whereas the mandible was rotated posteriorly.

# 3 Differences in FM/RME-treated Class III malocclusion patients and untreated controls

FM/RME-treated Class III malocclusion patients and untreated controls were also compared according to the five most revealing parameters. There was a significant improvement of the



PRISMA 2009 Flow Diagram



Fig 1. The flow chart of study selection. In this meta-analysis, 12 studies were selected for qualitative analysis.

doi:10.1371/journal.pone.0130096.g001

sagittal skeletal index in the FM/RME groups (Fig 3). Meta-analysis revealed that FM/RME is an obviously effective method for treating anterior cross-bite patients based on the following results: SNA (SMD = 1.39, 95% CI = 0.85-1.94, P < 0.00001); SNB (SMD = -2.54, 95% CI = -3.08--2.01, P < 0.00001); ANB (SMD = 3.25, 95% CI = 2.06-4.44, P < 0.00001); SN/GoGn

Table 1. Characteristics and methodological quality of the included studies.

Author	Year	Number	Study design	Quality score
Gencer	2014	FM group(n = 15); Control(n = 15)	Case-Control	28
Chen	2012	FM group(n = 22); Control(n = 17)	Case-Control	24
Ucem	2004	FM group(n = 14); Control(n = 14)	Case-Control	25
Kilicoglu	1998	FM/RME group(n = 16); Control (n = 10)	Case-Control	23
Masucci	2011	FM/RME group(n = 22); Control (n = 16)	Case-Control	26
Sar	2011	FM/RME group(n = 15); Control (n = 15)	Case-Control	24
Yuksel	2001	FM/RME group(n = 34); Control (n = 17)	Case-Control	26
Kajiyama	2000	FM/RME group(n = 29); Control (n = 25)	Case-Control	22
Lee	2010	Early treatment group (n = 26); Late treatment group (n = 23)	Case-Control	27
Franchi	2004	Early treatment group (n = 33); Late treatment group (n = 14)	Case-Control	24
Kajiyama	2004	Early treatment group (n = 63); Late treatment group (n = 57)	Case-Control	24
Baccetti	2000	Early treatment group (n = 32); Late treatment group (n = 28)	Case-Control	25

FM: face mask therapy. FM/RME: face mask and rapid maxillary expansion therapy

doi:10.1371/journal.pone.0130096.t001

FM VS Control												
1 SNA												
		FM		c	ontrol			Mean Difference		Mea	n Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Tota	Weight	IV, Fixed, 95% CI		IV. F	ixed. 95% CI	
Chen 2012	2.25	1.81	22	0.21	1	17	5.7%	2.04 [1.15, 2.93]			1 -	
Gencer 2014	1.9	0.34	15	0.2	0.3	15	86.9%	1.70 [1.47, 1.93]				
Kilicoglu 1998	2.56	1.55	16	0.05	1.33	10	3.6%	2.51 [1.39, 3.63]				
Ucem 2004	2.8	1.76	14	0.3	1.16	14	3.8%	2.50 [1.40, 3.60]				
Total (95% CI)			67			56	100.0%	1.78 [1.57, 1.99]			1	
Heterogeneity: Chi <sup>2</sup> =	4.06, df	= 3 (P	= 0.26	); I <sup>2</sup> = 2	6%				10	-5	0 5	10
Test for overall effect:	Z = 16.	30 (P <	< 0.000	01)					-10	-5	EM Control	10
2 SNB												
		FM		с	ontrol			Mean Difference		Me	ean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% (		IV,	Random, 95% CI	
Chen 2012	-1.18	1.94	22	0.88	1.25	17	16.9%	-2.06 [-3.07, -1.05	]		-	
Gencer 2014	-1.1	0.33	15	0.7	0.32	15	40.9%	-1.80 [-2.03, -1.57	]			
Kilicoglu 1998	-1.78	1.09	16	0.44	0.58	10	26.6%	-2.22 [-2.86, -1.58	]		•	
Ucem 2004	-0.2	1.91	14	0.3	0.71	14	15.6%	-0.50 [-1.57, 0.57	]		-	
											•	
Total (95% CI)			67			56	100.0%	-1.75 [-2.28, -1.23]			•	
Heterogeneity: Tau <sup>2</sup> =	0.16; CI	ni² = 7.	59, df =	= 3 (P =	0.06);	$l^2 = 60$	%		-10	-5	0 5	10
Test for overall effect:	Z = 6.55	6 (P < 0	0.00001	)						-	FM Control	
3 ANB												
		EM		0	ontrol			Mean Difference		Me	an Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV Random 95% (		IV F	Random 95% Cl	
Chap 2012	2.42	1 15	22	0.65	0.72	17	20.2%	4 07 12 49 4 661			-	
Gencer 2014	2.42	0.31	15	-0.05	0.15	15	40.5%	3 40 [3 22 3 58]				
Kilicoglu 1998	4 34	1.91	16	0.28	1.59	10	12 2%	4 62 12 20 5 94				
Licom 2004	4.54	1.01	14	-0.20	1.00	14	10.2%	2 00 [1 09 2 92]			-	
000112004	5	1.50	14	0.1	1.09	14	19.270	2.50 [1.50, 5.02]				
Total (95% CI)			67			56	100.0%	3.64 [3.10, 4.19]			•	
Heterogeneity: Tau <sup>2</sup> = (	0.18: Ch	ni <sup>2</sup> = 8.8	89. df =	3 (P =	0.03):	$ ^2 = 66$	%		H			-
Test for overall effect: 2	7 = 13.0	7 (P <	0.0000	1)	,				-10	-5	0 5	10
											FM Control	
A ANIC M												
4 AINS-Me		001107		100	1 10 1025			107 100.000				
		FM		C	ontrol			Mean Difference		Mean	Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fi	xed, 95% Cl	
Gencer 2014	3.8	0.49	15	0.9	0.44	15	86.8%	2.90 [2.57, 3.23]				
Kilicoglu 1998	3.75	1.66	16	0.44	1.1	10	8.6%	3.31 [2.25, 4.37]			_	
Ucem 2004	3.6	2.36	14	1.1	1.42	14	4.6%	2.50 [1.06, 3.94]				
T												
Total (95% CI)			45			39	100.0%	2.92 [2.61, 3.23]		1		
Heterogeneity: Chi <sup>2</sup> = 0	.86, df =	= 2 (P =	= 0.65);	$1^2 = 0\%$	0			5	10	-5	0 5	10
Test for overall effect: 2	2 = 18.4	1 (P <	0.0000	1)						F	M Control	
5001/0 0												
5 SN/GoGn												
		FM		Co	ontrol			Mean Difference		Me	an Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	1	IV, R	andom, 95% CI	
Chen 2012	2.46	1.75	22	-0.58	2.45	17	21.1%	3.04 [1.66, 4.42]				
Gencer 2014	0.8	0.38	15	-0.2	0.34	15	32.9%	1.00 [0.74, 1.26]			•	
Kilicoglu 1998	1.75	1.4	16	-0.61	1.24	10	25.3%	2.36 [1.33, 3.39]				
Ucem 2004	0.6	2.54	14	0.1	0.94	14	20.7%	0.50 [-0.92, 1.92]			-	
Total (95% CI)			67			56	100.0%	1.67 [0.63, 2.71]			•	
Heterogeneity: Tau <sup>2</sup> = 0	.83; Ch	i² = 14.	.62, df	= 3 (P =	0.002	);  ² = 7	79%		10	-		10
Test for overall effect: Z	= 3.16	(P = 0.	.002)						-10	-0	EM Control	10
											oomol	

**Fig 2.** The efficacy assessment of FM treatment for Class III malocclusion versus untreated controls. The comparison was performed using five indices. 1: Angle SNA. The FM treatment group presented a greater increase in SNA than the controls (SMD = 1.78, 95% Cl = 1.57-1.99, P < 0.00001). 2: Angle SNB. The FM treatment group presented a greater decrease in SNB than the untreated controls (SMD = -1.75, 95% Cl = -2.28-1.23, P < 0.00001). 3: Angle ANB. The FM treatment group presented a greater increase in ANB than the controls (SMD = 3.64, 95% Cl = 3.10-4.19, P < 0.00001). 4: ANS-Me length. The FM treatment group presented a greater increase in ANB than the controls (SMD = 3.64, 95% Cl = 3.10-4.19, P < 0.00001). 4: ANS-Me length. The FM treatment group presented a greater increase in ANS-Me length than the controls (SMD = 2.92, 95% Cl = 2.61-3.23, P < 0.00001). 5: Angle SN/GoGn. The FM treatment group presented a greater increase in SN/GoGn than the controls (SMD = 1.67, 95% Cl = 0.63-2.71, P = 0.002). The FM groups exhibited significant improvement in skeletal retrograthism of the maxilla.

doi:10.1371/journal.pone.0130096.g002

(SMD = 3.26, 95% CI = 2.34–4.18, P < 0.00001); and ANS-Me (SMD = 2.08, 95% CI = -0.21–4.36, P = 0.07).

# 4 Differences between the early treatment group and late treatment group

A comparison of the early treatment and late treatment groups is shown in Fig 4. Meta-analysis attempted to reveal whether FM therapy yields a greater response to maxillary protraction with an earlier initiation of treatment. Differences were observed in SNA (SMD = 1.09, 95% CI = -0.70-2.88, P = 0.23); SNB (SMD = -1.42, 95% CI = -1.95--0.90, P < 0.00001); ANB (SMD = 1.72, 95% CI = -0.76-4.19, P = 0.17); SN/GoGn (SMD = 0.5, 95% CI = -0.14-1.14,

1 SNA											
	F	M/RM	=	c	Control			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Tota	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed, 95% CI	
Kajivama 2000	1.48	1.93	29	0.05	2.07	25	25.8%	1.43 [0.36, 2.50]			
Masucci 2011	1.9	2.9	22	1.5	1.8	16	13.2%	0.40 [-1.10, 1.90]		-	
Sar 2011	1.83	1.33	15	0.26	0.53	15	56.6%	1.57 [0.85, 2.29]			
Yuksel 2001	1.9	4.06	17	0	3.68	17	4.4%	1.90 [-0.70, 4.50]		+	
Total (95% CI)			83			73	100.0%	1.39 [0.85, 1.94]		· ·	
Heterogeneity: Chi* =	= 2.07, df	= 3 (P	= 0.5t	$(5); 1^{2} = 0$	%				-10	-5 0 5	10
l est for overall effect	1: 2 = 5.0	1 (P < 1	0.0000	(11)						FM/RME Control	
2 SNB											
	FI	M/RME		с	ontrol			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Fixed, 95% CI		IV. Fixed, 95% CI	
Kaiiyama 2000	-1 37	1.92	29	0.82	1 72	25	30.4%	-2 19 [-3 16 -1 22]			
Masucci 2011	2	3.1	22	3.6	23	16	9.7%	-1 60 [-3 32 0 12]			
Sar 2011	-23	1 23	15	0.65	0.65	15	57.9%	-2 95 [-3 65 -2 25]			
Yuksel 2001	-0.4	4 93	17	0.00	6.24	17	2.0%	-0 70 [-4 48 3 08]			
1003012001	-0.4	4.00		0.0	0.24		2.070	-0.10[-4.40, 0.00]			
Total (95% CI)			83			73	100.0%	-2.54 [-3.08, -2.01]		•	
Heterogeneity: Chi2 =	3.86 df	= 3 (P	= 0.28	) 1 <sup>2</sup> = 22	29/	10	100.070	2.04[-0.00, 2.01]	<u> </u>		
Tost for overall offect	7 - 0.21	(P < 0	0.20	1)	2.70				-10	-5 0 5	10
rest for overall effect.	. 2 = 3.31	(	.0000	''						FM/RME Control	
3 ANB											
	EN	/RME		Co	ontrol			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV Random 95% C		IV Random 95% Cl	
Kaiwama 2000	2.95	2 70	20	0.77	1 22	25	25.0%	2 62 12 60 4 741			
Maguerei 2011	2.00	1.4	22	-2.1	1.6	16	27 49/	2 10 [1 12 3 08]			
Masucci 2011	4.0	1.4	45	-2.1	0.74	10	21.470	2.10 [1.12, 3.00]			
Sar 2011	4.2	1.90	15	-0.36	0.71	15	20.0%	4.56 [3.53, 5.63]			
YUKSEI 2001	2.3	2.1	17	-0.3	2.3	17	20.1%	2.60 [0.91, 4.29]			
Total (95% CI)			83			73	100.0%	3.25 [2.06, 4.44]		•	
Heterogeneity: Tau <sup>2</sup> =	1 10 <sup>.</sup> Ch	$i^2 = 12$	40 df	= 3 (P =	0.006	· 12 = 7	6%		H		
Test for overall effect:	7 = 5 36	(P < 0	00001	1	01000		010		-10	-5 0 5	10
		(		,						FM/RME Control	
4 ANS-Me											
	FM	/RME		Co	ontrol			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD 1	Total	Mean	SD 1	Total	Weight	IV, Random, 95% C		IV, Random, 95% CI	
Kajiyama 2000	4.26	2.72	29	0.8	1.52	25	29.8%	3.46 [2.30, 4.62]			
Masucci 2011	6.5	2.3	22	8.2	3.8	16	25.4%	-1.70 [-3.80, 0.40]			
Sar 2011	3.96	1.74	15	0.1	0.91	15	30.4%	3.86 [2.87, 4.85]		-	
Yuksel 2001	3.1	7.85	17	1	5.13	17	14.5%	2.10 [-2.36, 6.56]			
Tetal (05%/ CI)			02			72	100.0%	2 09 1 0 24 4 261			
Hotorogonoitu: Touž =	4 20: Chi	2 - 22	05 df	= 2 (P <	0.000	1): 12 -	070/	2.00 [-0.21, 4.30]	<u> </u>		
Tost for overall effect:	4.20; Chi 7 = 1 70	- 22.	90, dr	- 5 (P C	0.000	, i <sup>2</sup> = .	01 70		-10	-5 0 5	10
rest for overall effect:	2 - 1.78	(r <sup>.,</sup> = 0.	01)							FM/RME Control	
5 SN/GoGn											
	FM,	RME		C	ontrol			Mean Difference		Mean Diff	erence
Study or Subgroup	Mean	SD .	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C		IV, Fixed,	95% CI
Kajiyama 2000	2.74	3.69	29	-0.43	2.54	25	30.3%	3.17 [1.50, 4.84	H]		_
Sar 2011	3.06	2.07	15	-0.4	0.87	15	65.6%	3.46 [2.32, 4.60	0]		_
Yuksel 2001	0.8	8.08	17	0.1	5.19	17	4.1%	0.70 [-3.87, 5.27	7]		
Total (95% CI)			61			57	100.0%	3.26 [2.34, 4.18	1		٠
Heterogeneity: Chi <sup>2</sup> -	1.34 df	= 2 / 1	= 0	51): 1 <sup>2</sup> -	: 0%	57	100.07		″ —		-
Test for overall effect:	Z = 6.94	1 (P <	0.000	01)	010				-10	-5 0	Ś
				/						FM/KME C	ontrol

**Fig 3.** The efficacy assessment of FM/RME treatment for Class III malocclusion versus untreated controls. The comparison was performed using five indices. 1: Angle SNA. The FM treatment group presented a greater increase in SNA than the controls (SMD = 1.39, 95% CI = 0.85-1.94, P < 0.00001). 2: Angle SNB. The FM treatment group presented a greater decrease in SNB than the untreated controls (SMD = -2.54, 95% CI = -3.08--2.01, P < 0.00001). 3: Angle ANB. The FM treatment group presented a greater increase in ANB than the controls (SMD = 3.25, 95% CI = 2.06-4.44, P < 0.00001). 4: ANS-Me length. The FM treatment group presented a greater increase in ANS-Me length. The FM treatment group presented a greater increase in ANS-Me length than the controls (SMD = 2.08, 95% CI = -0.21-4.36, P = 0.07). 5: Angle SN/GoGn. The FM treatment group presented a greater increase in SN/GoGn than the controls (SMD = 3.26, 95% CI = 2.34-4.18, P < 0.00001). The FM/RME groups exhibited significant improvement in skeletal retrognathism of the maxilla.

doi:10.1371/journal.pone.0130096.g003

FM + RME VS Control

P = 0.13); Co-Gn (SMD = 2.94, 95% CI = -3.78–9.74, P = 0.4); and ANS-Me (SMD = 0.50, 95% CI = -1.87–2.86, P = 0.68). Following quantitative calculation on the lateral cephalograms, no significant differences were noted between the two groups. In other words, early treatment did not significantly improve modifications in both maxillary and mandibular structures over the results achieved by late treatment group. However, it is even more important to note that some children with permanent teeth can be treated as the late group to improve skeletal crossbite deformity, allowing the avoidance of some unnecessary orthognathic surgeries.

#### 5 Sensitivity analysis

For each measurement index of FM and FM/RME, we chose 3 relatively high-quality studies (score  $\geq$ 4) to carry out the sensitivity analysis (shown in Figs 5 and 6). Compared with the control group and with the FM group, the maxillary protractor FM groups showed significant

					0.00							
Physics on Parkaneses	Early tr	eatment	group	Late treatment group				Mean Difference	Mean Difference			
Study or Subgroup	Mean	50	lota	Mean	0.74	Tota	vveight	IV. Random, 95%	CI IV. Random, 95% CI			
Lee 2010	2.24	1.44	26	2.07	1.77	2	9 43.9% 3 41.2%	2.24 [1.09, 2.78				
Yuksel 2001	1.9	4.06	17	1.65	6.88	1	7 15.0%	0.25 [-3.55, 4.05	51			
Total (95% CI)	1 00. 01.3		77		12 - 070	69	9 100.0%	1.09 [-0.70, 2.88				
Heterogeneity: Tau* = Test for overall effect:	Z = 1.19 (	= 15.55, P = 0.23)	df = 2 (P	= 0.0004)	; 1* = 87%	>			-10 -5 0 5			
		,							Early treatment group Late treatment gro			
2 SNB												
	Early tre	eatment	group	Late tre	eatment g	group		Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Tota	Weight	IV, Fixed, 95% CI	IV. Fixed, 95% CI			
Kajiyama 2004	-4.01	1.9	34	-2.19	0.78	29	57.2%	-1.82 [-2.52, -1.12]				
ee 2010 /ukeel 2001	-1./5	1.33	26	-0.78	1.59	23	40.9%	-0.97 [-1.80, -0.14]				
013612001	-0.4	4.00		-1.07	0.04		1.070	0.07 [-0.10, 4.40]				
otal (95% CI)			77			69	100.0%	-1.42 [-1.95, -0.90]	•			
leterogeneity: Chi <sup>2</sup> =	3.55, df = 2	(P = 0.1	7); l <sup>2</sup> = 44	%					-10 -5 0 5			
est for overall effect:	Z = 5.28 (P	< 0.0000	01)						Early treatment group Late treatment group			
ANB												
	Early tre	atment g	roup	Late tre	atment g	roup		Mean Difference	Mean Difference			
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% C	I IV. Random, 95% CI			
ajiyama 2004	7.68	2.46	34	3.62	0.55	29	35.3%	4.06 [3.21, 4.91]				
ee 2010	4	1.8	26	2.85	1.38	23	35.1%	1.15 [0.26, 2.04]				
uksel 2001	2.3	2.7	17	2.7	3.24	17	29.6%	-0.40 [-2.40, 1.60]	-			
otal (95% CI)			77			69	100.0%	1.72 [-0.76, 4.19]	-			
eterogeneity: Tau <sup>2</sup> =	4.35: Chi?	20.65	f = 2 (P <	0.00001)	12 = 0392							
est for overall effect:	Z = 1.36 (P	= 0.17)	20	0.00001)	,1 - 50 /				-10 -5 0 5 Early treatment group Late treatment group			
est for overall effect: a	Z = 1.36 (P	= 0.17)		Late tree	atment a	roup		Maan Diffarance	-10 -5 0 5 Early treatment group Late treatment group			
est for overall effect: 2 ANS-Me udv or Subaroup	Early trea	= 0.17)	roup	Late trea	atment g	roup	Weight	Mean Difference	-10 -5 0 5 Early treatment group Late treatment grou Mean Difference IV, Random, 95% CI			
est for overall effect: ; ANS-Mc tudy or Subgroup accetti 2000	Early tree Mean 2.63	atment g 2.46	roup Total	Late trea Mean 3.6	atment g <u>SD</u> 3.16	roup Total	Weight 38.9%	Mean Difference IV. Random. 95% CI -0.97 [-3.07, 1.13]	-10 -5 0 5 Early treatment group Late treatment grou Mean Difference IV. Random. 95% Cl			
est for overall effect: 2 ANS-Mc udy or Subgroup locetti 2000 lijyama 2004	Early trea Mean 2.63 5.34	atment g 2.46 2.98	roup Total 16 34	Late trea Mean 3.6 3.46	atment g <u>SD</u> 3.16 0.87	roup Total 13 29	Weight 38.9% 50.4%	Mean Difference IV. Random, 95% CI -0.97 [-3.07, 1.13] 1.88 [0.83, 2.93]	-10 -5 0 5 5 Early treatment group Late treatment grou Mean Difference IV. Random, 95% CI			
est for overall effect: 2 ANS-Me udy or Subgroup accetti 2000 ijiyama 2004 iksel 2001	Early trea <u>Mean</u> 2.63 5.34 3.1	atment g 2.46 2.98 7.85	roup Total 16 34 17	Late trea Mean 3.6 3.46 3.8	atment g SD 3.16 0.87 11.16	roup <u>Total</u> 13 29 17	Weight 38.9% 50.4% 10.8%	Mean Difference IV. Random. 95% Ci -0.97 [-3.07, 1.13] 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79]	-10 -5 0 5 Early treatment group Late treatment grou Mean Difference IV. Random. 95% Cl			
est for overall effect: 3 ANS-Me tudy or Subgroup accetti 2000 ajiyama 2004 Jiksel 2001	Early tree Mean 2.63 5.34 3.1	atment g SD 2.46 2.98 7.85	roup Total 16 34 17	Late trea Mean 3.6 3.46 3.8	atment gr SD 3.16 0.87 11.16	roup Total 13 29 17	Weight 38.9% 50.4% 10.8%	Mean Difference IV. Random. 95% Ci -0.97 [-3.07, 1.13] 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79]	-10 -5 0 5 Early treatment group Late treatment grou Mean Difference IV. Random, 95% CI			
est for overall effect: 2 ANS-Mc udy or Subgroup sccetti 2000 sjiyama 2004 sksel 2001 stal (95% CI)	Early tree <u>Mean</u> 2.63 5.34 3.1	atment g <u>SD</u> 2.46 2.98 7.85	roup <u>Total</u> 16 34 17 67	Late tree <u>Mean</u> 3.6 3.46 3.8	atment g SD 3.16 0.87 11.16	roup Total 13 29 17 59	Weight 38.9% 50.4% 10.8% 100.0%	Mean Difference IV. Random. 95% CI -0.97 [-3.07, 1.13] 1.86 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86]	-10 -5 0 5 5 Early treatment group Late treatment grou Mean Difference IV. Random. 95% Cl			
est for overall effect: 2 ANS-Mc accetti 2000 ajyama 2004 Juksel 2001 Jotal (95% CI) setorogeneity: Tau <sup>2</sup> = 2 est for overall effect: Z	Early tree Mean 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = 2 = 0.41 (P	atment g SD 2.46 2.98 7.85 6.03, df = = 0.68)	roup 16 34 17 67 = 2 (P = 0	Late trea <u>Mean</u> 3.6 3.46 3.8	atment g SD 3.16 0.87 11.16	roup <u>Total</u> 13 29 17 59	Weight 38.9% 50.4% 10.8% 100.0%	Mean Difference <u>IV. Random. 95% CI</u> -0.97 [-307, 1.13] 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86]	Mean Difference IV. Random. 95% Cl Mark treatment group Mean Difference IV. Random. 95% Cl Mean Difference IV. Rando			
est for overall effect: 2 ANS-Mc udy or Subgroup accetti 2000 ajyama 2004 uksel 2001 stal (95% Cl) neterogeneity: Tau <sup>2</sup> = 2 est for overall effect: 2 SN/GoGn	Early trea Mean 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = = 0.41 (P -	atment g <u>SD</u> 2.46 2.98 7.85 6.03, df = = 0.68)	roup <u>Total</u> 16 34 17 67 = 2 (P = 0	Late tree <u>Mean</u> 3.6 3.46 3.8	atment g SD 3.16 0.87 11.16	roup Total 13 29 17 59	Weight 38.9% 50.4% 10.8% 100.0%	Mean Difference IV. Random. 95%. [13] 0.97 [-3.07, 2.07] 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86]	-10 -5 0 5 Early treatment group Late treatment group Weam Difference IV. Randem. 95% CI			
est for overall effect: 2 ANS-Me udy ar Subgroup scoetti 2000 sjiyama 2004 uksel 2001 batal (95% Cl) tetorgeneity: Tau <sup>2</sup> = 2 sat for overall effect: 2 SN/GoGn	Early tree Mean 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = 0.41 (P <sup>2</sup> Early tree	atment g <u>SD</u> 2.46 2.98 7.85 6.03, df = 0.68)	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 roup Total	Late trea <u>Mean</u> 3.6 3.46 3.8 1.05); l <sup>2</sup> = ( Late trea Mean	atment g SD 3.16 0.87 11.16 67%	roup <u>Total</u> 13 29 17 59 59	Weight 38.9% 50.4% 10.8% 100.0% N Weight	Mean Difference IV. Random. 35%; CJ 0.97 [-3.07, 1.13] 1.88 [0.83, 2.93] 0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86]	Head Difference N. Random, 95% Cl. Head Difference N. Random, 95% Cl. Head Difference N. Random, 95% Cl. Head Difference N. Band Difference N. Band Difference N. Band Difference N. Band Difference N. Band Difference N. Band Difference			
est for overall effect: 2 ANS-Me udy or Subgroup accett 2000 ijiyama 2004 aksel 2001 tati (95% CI) sterogeneity: Tau <sup>2</sup> = 2 st for overall effect: 2 its/GoGn udy or Subgroup_ itsoma 2004	Early trea Mean 2.61; Chi <sup>2</sup> = 2.61; Chi <sup>2</sup> = 2.61; Chi <sup>2</sup> = 2.61; Chi <sup>2</sup> = 4.61; Chi <sup>2</sup> = 4.61; Chi <sup>2</sup> = 5.34 3.1	atment g <u>SD</u> 2.46 2.98 7.85 6.03, df = 0.68) ttment ga <u>SD</u> 2.5	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 roup <u>Total</u> 34	Late trea <u>Mean</u> 3.6 3.46 3.8 0.05); l <sup>2</sup> = ( Late trea <u>Mean</u> 3.17	atment g SD 3.16 0.87 11.16 67%	roup <u>Total</u> 13 29 17 59 59 oup <u>Total</u> 29	Weight 38.9% 50.4% 10.8% 100.0% N Weight 49.8%	Mean Difference <u>IV. Random. 95% CI</u> -0.97 (-3.07, 1.13) 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86] Isan Difference <u>IV. Fixed. 95% CI</u> 0.42 (-0.49 1.5% CI	Heam Difference Keading and the treatment group Meam Difference N. Randym. 95% Cl Heating and the treatment group Late treatment group Late treatment group Meam Difference N. Eixed, 95% Cl			
est for overall effect: 2 ANS-Me udy or Subgroup coceti 2000 iyuma 2004 ksel 2001 tarogeneity: Tau <sup>2</sup> = 2 ist for overall effect: 2 ist/GoGn udy or Subgroup iyuma 2004 e 2010	Early tree Mean 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = 2.6.41 (P - Early trea Mean 3.59 1.81	atment g SD 2.46 2.98 7.85 6.03, df = = 0.68) atment gr SD 2.5 1.63	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 roup <u>Total</u> 34 26	Late trea <u>Mean</u> 3.6 3.46 3.8 1.05); l <sup>2</sup> = ( Late trea <u>Mean</u> 3.17 1.21	atment gr 3.16 0.87 11.16 67% stment gr 0.93 1.62	roup <u>Total</u> 13 29 17 59 oup <u>Total</u> 29 23	Weight 38.9% 50.4% 10.8% 100.0% N Weight 49.8% 49.1%	Mean Difference IV. Random. 35%, CI -0.97 [-3.07, 1.13] 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86] 0.50 [-1.87, 2.86] V. Fixed. 35%, CI 0.42 [-0.49, 1.33] 0.42 [-0.49, 1.33]	How an Difference     Weat Difference     V. Random, 95% CI     Difference     V			
est for overall effect: 2 ANS-Me udy or Subgroup accetti 2000 hjyama 2004 aksel 2001 vtal (85% CI) tal (85% C	Early tree <u>Mean</u> 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = 0.41 (P <sup>2</sup> Early trea <u>Mean</u> 3.59 1.81 0.8	atment g SD 2.46 2.98 7.85 6.03, df = = 0.68) atment gr SD 2.5 1.63 8.08	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 <u>Total</u> 34 26 17	Late trea <u>Mean</u> 3.6 3.46 3.8 1.05); l <sup>2</sup> = ( Late trea <u>Mean</u> 3.17 1.21 1.3	atment g SD 3.16 0.87 11.16 67% atment gr 0.93 1.62 9.94	roup 13 29 17 59 0up <u>Total</u> 29 23 17	Weight 38.9% 50.4% 10.8% 100.0% Weight 49.8% 49.1% 1.1%	Mean Difference IV. Random. 95% CI -0.97 [-3.07, 1.13] 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86] Mean Difference IV. Fixed. 95% CI 0.42 [-0.49, 1.5] 0.60 [-0.31, 1.51] 0.60 [-6.5, 5.59]	Mean Difference V. Randem 95% Cl Mean Difference V. Randem 95% Cl Mean Difference V. Exed. 95% Cl Mean Difference			
est for overall effect: 2 ANS-Me udy or <u>Subgroup</u> isocetil 2000 ijiyama 2004 isocetil 2000 ijiyama 2004 isot for overall effect: 2 isN/GoGn udy or <u>Subgroup</u> ijiyama 2004 e 2010 ksol 2001 ht/05EC f0	Early trea Mean 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = 2 = 0.41 (P - Mean 3.59 1.81 0.8	atment g <u>SD</u> 2.46 2.98 7.85 6.03, df = 0.68) timent gi <u>SD</u> 2.5 1.63 8.08	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 Total 34 26 17 77	Late trea <u>Mean</u> 3.6 3.46 3.8 1.05); l <sup>2</sup> = 6 Late trea <u>Mean</u> 3.17 1.21 1.3	atment g 3.16 0.87 11.16 67% timent gr 0.93 1.62 9.94	roup <u>Total</u> 29 17 59 000p <u>Total</u> 29 23 17	Weight 38.9% 50.4% 10.8% 100.0% Weight 49.8% 49.1% 1.1%	Mean Difference IV. Random. 35%, CI -0.97 (-3.07, 1.13) 1.88 (0.83, 2.03) -0.70 (-7.18, 5.79) 0.50 (-1.87, 2.86) No (-1.87, 2.86) No (-1.87, 2.86) V. Fixed. 95%, CI 0.42 (-0.49, 1.33) 0.60 (-0.31, 1.51) 0.50 (-50, 5.55)	Head Difference     K. Random, 95%, Cl     Mean Difference     K. Kandom, 95%, Cl     Mean Difference     K. Kandom, 95%, Cl     Mean Difference     K. Fixed, 95%, Cl			
est for overall effect: 2 ANS-Mc udy or <u>Subgroup</u> socotti 2000 ijiyama 2004 kisel 2001 vtal (95% CI) tel (95% CI)	Z = 1.36 (P Early tree <u>Mean</u> 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = = 0.41 (P - <u>Mean</u> 3.59 1.81 0.8 18 df = 2.0	atment g <u>SD</u> 2.46 2.98 7.85 6.03, df = 0.68) atment gi <u>SD</u> 2.5 1.63 8.08 P = 0.91	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 <u>Total</u> 34 26 17 77 77	Late tree <u>Mean</u> 3.6 3.46 3.8 1.05); l <sup>2</sup> = 6 Late tree <u>Mean</u> 3.17 1.21 1.3	atment gr 3.16 0.87 11.16 57% atment gr 0.93 1.62 9.94	roup <u>Total</u> 13 29 17 59 Total 29 23 17 69	Weight 38.9% 50.4% 10.8% 100.0% N Weight 49.8% 49.1% 1.1% 1.1%	Mean Difference <u>IV. Random. 95%</u> , [1] -0.97 [-0.17, 1] 1.88 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86] Mean Difference <u>IV. Fixed. 95%</u> , [1] 0.42 [0.49, 1.33] 0.69 [-0.31, 1.51] 0.50 [-5.59]	Mean Difference IV, Bandom, 95%, Cl Mean Difference IV, Bandom, 95%, Cl Mean Difference IV, Exect 95%, Cl Mean Difference IV, Exect, 95%, Cl Mean Difference			
Test for overall effect: 2 I ANS-Me Itady or Subgroup Jaccett 2000 Jajyama 2004 uksel 2001 for overall effect: 2 SN/GoGn tudy or Subgroup Jajyama 2004 ee 2010 uksel 2001	Early trea <u>Mean</u> 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = 2 = 0.41 (P - Early trea <u>Mean</u> 3.59 1.81 0.8	atment g SD 2.46 2.98 7.85 6.03, df = 0.68) etment gr SD 2.5 1.63 8.08	roup <u>Total</u> 16 34 26 17	Late tree <u>Mean</u> 3.6 3.46 3.8 0.05); l <sup>2</sup> = 0 Late trea <u>Mean</u> 3.17 1.21 1.3	atment g 3.16 0.87 11.16 67% timent gr 0.93 1.62 9.94	roup <u>Total</u> 13 29 17 59 oup <u>Total</u> 29 23 17	Weight 38.9% 50.4% 10.8% 100.0% N Weight 49.8% 49.1% 1.1%	Mean Difference IV. Random. 35%, CI 1.88 [0.83, 2-93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86] Mean Difference IV. Fixed. 95%, CI 0.42 [-0.49, 1.33] 0.60 [-0.31, 1.51] 0.50 [-6.59, 5.59]	-10 -5 0 5 Early treatment group Late treatment g Wean Difference IV. Random, 95% CI -10 -5 0 5 1 Early treatment group Late treatment gro Mean Difference IV. Fixed, 95% CI			
Test for overail effect: 2 I ANS-Me Hutly of Subgroup ajjvama 2004 uhsel 2001 detrogeneity: Tau <sup>2</sup> = 2 est for overail effect: 2 SN/GoGn Hutly of Subgroup jyarma 2004 te 2001 jxkel 2001 sterogeneity: Chi <sup>2</sup> = 0. ist (of overail effect: 2	Z = 1.36 (P Early tree <u>Mean</u> 2.63 5.34 3.1 2.61; Ch <sup>2</sup> = 0.41 (P Early trea <u>Mean</u> 3.59 1.81 0.8 18, df = 2 (I = 1.53 (P =	atment g SD 2.46 2.98 7.85 6.03, df : e 0.68) ttment gr SD 2.5 1.63 8.08 P = 0.91) e 0.13)	roup Total 16 34 26 17 77 77 1 <sup>2</sup> = 0%	Late tree <u>Mean</u> 3.6 3.8 0.05); l <sup>2</sup> = ( Late tree <u>Mean</u> 3.17 1.21 1.3	atment g SD 3.16 0.87 11.16 67% 5D 0.93 1.62 9.94	roup <u>Total</u> 13 29 17 59 59 59 0 0 0 0 0 0 0 0 0 0 0 17 59 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Weight 38.9% 50.4% 10.8% 40.0% <b>Weight</b> 1.1% 1.1%	Mean Difference IV. Random, 35% CI -0.97 (-3.07, 1.13) 1.86 (10.8, 7.09) -0.70 (-7.16, 7.79) 0.50 (-1.87, 2.86) N. Encol. 95% CI V. Encol. 95% CI 0.50 (-0.31, 1.51) 0.50 (-0.14, 1.14) -1( Es	And Difference Nean Difference N. Random 395% Cl N. Random 395% Cl And Difference N. Fixed, 395% Cl N.			
est for overall effect: 2 ANS-Me tudy or Subgroup accetti 2000 algiama 2004 uksel 2001 otal (85% CI) eterogeneily: Tau's = 2 SN/GoGn udy or Subgroup ayama 2004 e 2010 skol 2004 e 2010 staferogeneily: Chir = 0. stof or overall effect: Z CoGn	Z = 1.36 (P <u>Mean</u> 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = z = 0.41 (P <u>Mean</u> 3.59 1.81 0.8 18, df = 2 (I = 1.53 (P =	atment g <u>SD</u> 2.46 2.96 2.46 2.98 6.03, df : 6.03, df : <u>SD</u> 2.5 1.63 8.08 P = 0.91) = 0.13)	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 <b>Total</b> 26 17 77 77 (P = 0%	Late trea <u>Mean</u> 3.46 3.48 (05); P = ( <u>Mean</u> <u>Mean</u> 1.21 1.3	atment g <u>SD</u> 11.16 67% tment gr <u>SD</u> 0.87 11.16 67%	roup <u>Total</u> 13 29 17 59 Total 29 23 17 69	Weight 38.9% 50.4% 10.8% 100.0% 8.49.1% 49.8% 49.1% 1.1.1%	Mean Difference <u>IV. Random, 95% CI</u> -0.97 (-3.07, 81, 82, 83) -0.70 (-7.18, 5.79) 0.50 (-1.87, 2.86) M. Fixed, 95% CI M. Fixed, 95% CI 0.42 (-0.40, 1.53) 0.60 (-0.31, 1.61) 0.50 (-0.14, 1.14) -1( Es	Hean Difference I. Early treatment group Late treatment group Mean Difference IV. Random, 95% Cl Hean Difference IV. Eixed, 95% Cl Hean Difference IV. Fixed, 95% Cl Hean Difference IV. Fixed, 95% Cl Hean Difference IV. Fixed, 95% Cl Hean Difference IV. Fixed, 95% Cl Hean Difference IV. Eixed, 95% Cl H			
est for overall effect: 2 ANS-Me Ludy or Subgroup accent 2000 accent 2000 accent 2000 accent 2000 accent 2000 leterogeneity: Tau <sup>2</sup> = 2 accent 2004 accent 2004 acc	$Z = 1.36 (P \\ \frac{Mean}{2} \\ Z = 0.41 (P \\ 1.81 (P \\ 1.8$	atment g SD 2.46 6.03, df / 2.98 7.85 6.03, df / 2.98 7.85 6.03, df / 2.98 8.08 P = 0.91) 9 = 0.91)	roup <u>Total</u> 16 34 17 67 72 10 10 10 10 10 10 10 10 10 10	Late tree Mean 3.6 3.6 3.6 3.6 3.7 1.2 1.3 1.3	atment gr SD 0.87 11.16 67% tment gr 0.93 1.62 9.94	roup <u>Total</u> 13 29 17 59 000 <u>Total</u> 29 23 17 69 09	Weight 38.9% 50.4% 10.0% 100.0% Weight 49.8% 49.1% 1.1% 100.0%	Mean Difference IV. Bandom 355, CI 957 [-07.13] 958 [0.83, 293] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86] Mean Difference IV. Exced. 95%, CI 0.42 [-0.49, 1.33] 0.60 [-0.31, 1.51] 0.50 [-0.14, 1.14] Ean Difference	And Difference Nearn Difference N. Randem 95% Cl N. Randem 95% Cl And State Treatment group Late treatment group Mean Difference N. Eixed, 95% Cl And State Treatment group Mean Difference N. Eixed, 95% Cl And State Treatment group Late treatment group Late treatment group			
est for overall effect: 2 ANS-Mc tudy or Subgroup accetti 2000 siyama 2004 skeel 2001 tati (95% CI) elenogeneity: Turi" = 2 elst for overall effect: 2 SN/GoGn udy or Subgroup stat (95% CI) terogeneity: CI)rt" = 0, st for overall effect: 2 coGn	Z = 1.36 (P Early treat 2.63 5.34 3.4 1.61; Ch <sup>2</sup> = 0.41 (P Kany treat 0.8 1.81 0.85 1.81 0.85 1.81 0.85 1.81 0.85 1.81 0.85 1.81 0.85 1.81 0.85 1	atment g <u>SD</u> 2.46 2.98 7.85 6.03, df ( 8.08) 2.5 1.63 8.08 P = 0.91) = 0.13) ment gra	roup <u>Total</u> 16 34 17 67 = 2 (P = 0 <u>Total</u> 17 77 77 77 77 77 77 77	Late treat <u>Mean</u> 3.66 3.86 3.65; l <sup>2</sup> = ( Late treat <u>Mean</u> 1.3 Late treat <u>Mean</u>	atment gr 3.16 0.87 11.16 67% 5D 0.93 1.62 9.94	roup <u>Total</u> 13 29 17 59 0up <u>Total</u> 29 29 29 20 29 29 17 69 9 17 69	Weight	Mean Difference <u>IV. Random. 95% CI.</u> 1.097 [-3.07, 1.13] 1.88 [0.83, 2.93] 0.50 [-1.87, 2.86] 1.000 [-1.87, 2.86] 1.000 [-0.13, 1.51] 0.50 [-0.14, 1.33] 0.50 [-0.14, 1.33] 0.50 [-0.14, 1.34] -1. Ean Mean Difference V. Random. 95% CI.	Hoan Difference     W. Fixed, 95% Cl      Mean Difference     W. Randem, 95% Cl      Mean Difference     W. Randem, 95% Cl			
est for overall effect: 2 ANS-Me udy or Subgroup socett 2000 stal (95% CI) terogeneity: Tau <sup>2</sup> = 2 its//GoGn udy or Subgroup its for overall effect: 2 its//GoGn udy or Subgroup or overall effect: 2 its or overall effect = 1 its or overall effect = 1	Z = 1.36 (P Early tree Mean 2.63 3.1 2.61; Chi <sup>2</sup> = 0.41 (P Early tree Mean 1.81 0.8 18, d1 = 2 (2 1.53 (P Early treet Mean Mean Mean 0.95	atment g SD 2.46 2.46 6.03, df 1 2.5 6.03, df 4 2.5 1.63 8.08 P = 0.911 = 0.13)	roup <u>Total</u> 34 16 67 72 17 77 77 77 77 77 77 77 77 77	Late treat <u>Mean</u> 3.6 3.6 3.6 1.21 1.3 Late treat <u>Mean</u> 1.7 1.7	atment gr <u>SD</u> 0.93 11.16 67% tment gr <u>SD</u> 9.94 ment grc	roup <u>Total</u> 13 29 17 59 17 59 20 23 17 69 20 23 17 69 13 13	Weight 38.9% 50.4% 10.6% 100.0% Weight 1.1% 1.1% 1.1% 38.9%	Mean Difference IV. Barden, 395:40 397 [-0.7, 1.13] 1.86 [0.83, 2.93] -0.70 [-7.19, 5.79] 0.50 [-1.87, 2.86] Mean Difference IV. Fixed, 95% CI 0.50 [-0.14, 1.33] 0.60 [-0.31, 1.51] 0.50 [-0.14, 1.14] -11 Ean Mean Difference V. Random, 95% CI -0.75 [-2.00, 0.59]	Mean Difference IV, East between group Late treatment group Mean Difference IV, East between group Late treatment group Mean Difference IV, Exadem SS% CL Mean Difference IV, Exadem SS% CL Mean Difference IV, Randem SS% CL			
est for overall effect: 2 ANS-Mc udy or Subgroup cootil 2000 ujiyama 2004 ksel 2001 tati (95% CI) terogeneity: Tau* = 2 ksi for overall effect: 2 ks/GoGn udy or Subgroup iyama 2004 ksel 2001 tati (95% CI) terogeneity: CI)* = 0, st for overall effect: 2 coGn dy.or.Subgroup cetti 2000 hi 2004	Z = 1.36 (P Early treat 2.63 5.34 3.1 2.61; Chi <sup>2</sup> = 0.41 (P       	atment g <u>SD</u> 2.96 7.85 6.03, df 1 = 0.68) ttment gr <u>SD</u> 2.5 1.63 8.08 P = 0.911 = 0.13) ment gr <u>SD</u> 5.7	roup Total 16 34 17 67 2 ( $P = 0$ 2 ( $P = 0$ 34 26 17 77 77 77 77 77 77 77 77 77	Late treat Mean 	atment gr SD 0.87 11.16 67% ttment gr SD 9.94 ment gr SD 1.74 5.9	roup <u>Total</u> 13 29 17 59 17 59 20 23 17 69 17 69 <u>Total</u> 17 13 17 17 13 17 17 13 17 13 17 17 17 17 17 17 17 17 17 17	Weight 38.9% 50.4% 10.8% 100.0% 49.1% 1.1% 1.1% 36.9% 36.9%	Mean Difference <u>IV. Random. 25% CI.</u> 0.097 [-3.07, 1.13] 1.88 [0.83, 2.39] 0.50 [-1.87, 2.86] 1.87, 2.86] 1.80 [-1.87, 2.86] 1.80 [-1.87, 2.86] 1.80 [-1.87, 2.86] 1.80 [-1.87, 2.96] 1.80 [-1.87, 2.96] 1.80 [-1.87, 2.96] 1.80 [-1.87, 2.96] 1.80 [-1.97, 2.96] 1.90 [-1.97,	Mean Difference IV. Fixed, 85% Cl. Mean Difference IV. Fixed, 85% Cl. Mean Difference IV. Fixed, 85% Cl. Mean Difference IV. Fixed, 85% Cl. Mean Difference IV. Randem, 95% Cl.			
est for overall effect: 2 ANS-Me udy or Subgroup coeff 2000 skel 2001 stal (95% CI) terogeneity: Tau <sup>2</sup> = 2 its//GoGn dy or Subgroup jyama 2004 s 2010 ksol 2001 tal (95% CI) terogeneity: Chi <sup>2</sup> = 0, it for overall effect: 2 oGn dy or Subgroup octi 2000 schi 2004 sel 2001	$ \begin{split} & \text{Early tree} \\ & \text{Early tree} \\ & \text{Mean} \\ & 2.63; Chi^2 = 0.41 \ (P + 1) \\ & \text{Mean} \\ & \text{Mean} \\ & 0.8 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.81 \\ & 0.81 \\ & 1.$	atment g <u>SD</u> 2.46 2.98 7.85 6.03, df 4 2.98 6.03, df 4 1.63 8.08 P = 0.913 1.63 8.08 P = 0.913 1.93 5.7 8.44	roup Total 16 34 17 67 67 17 18 28 17 77 17 10 10 10 10 10 10 10 10 10 10	Late treat Mean 3.6 3.46 3.8 3.6 3.7 1.21 1.3 Late treat Mean 1.7 1.7 1.2 2	ment gr SD 0.87 11.16 67% ttment gr SD 1.62 9.94 ment gr SD 1.62 9.94	roup <u>Total</u> 13 29 17 59 10 17 69 10 10 11 17 17	Weight 38.9% 50.4% 10.8% 10.0% Weight 100.0% 100.0% 100.0% 100.0%	Mean Difference 17. Earden	Mean Difference IV, Exadement group Late treatment group Mean Difference IV, Exadem 35% Cl Mean Difference IV, Randem 35% Cl			
est for overall effect: 2 ANS-Mc udy or Subgroup locotti 2000 locotti 2000 locott	$ \begin{array}{l} {\rm Early treat} \\ {\rm Early treat} \\ {\rm Zen} \\ {\rm$	atment g <u>SD</u> 2.46 2.46 2.46 2.46 2.58 7.85 6.03, df // 8.08 P = 0.91) 0.13) ment grd <u>SD</u> 1.63 8.08 P = 0.91) 5.7 8.44	roup <u>Total</u> 16 34 17 67 72 18 26 17 77 77 77 77 77 77 77 77 77	Late tree Mean 3.6 3.46 3.8 .05); I <sup>2</sup> = ( Late trea Mean 1.3 1.3	stment gr sb) 11.16 57% trment gr sb) 9.94 ment gr 5.9 9.59	roup <u>Total</u> 13 29 17 59 59 0 0 0 0 0 0 0 0 17 59 0 17 69 13 17 69 13 17 13 17 17 69 13 17 17 17 17 17 17 17 17 17 17	Weight 38.9% 50.4% 100.0% Weight 49.5% 1.1% 1.1% 1.1% 49.5% 36.9% 34.2% 36.9% 34.2%	Mean Difference <u>IV. Random. 25% CI.</u> 0.097 [-3.07, 1.13] 1.88 [0.83, 2.39] 0.50 [-1.87, 2.86] 1.87, 2.86] 1.80 [-1.87, 2.86] 1.80 [-1.87, 2.86] 1.80 [-1.87, 2.86] 1.80 [-1.87, 2.86] 1.80 [-1.87, 2.96] 1.80 [-1.87, 2.97] 1.80 [-1.87, 2.97] 1.80 [-1.97, 2.97] 1.80 [-1.97, 1.27] 1.80 [-1.97, 1.27] 1.80 [-1.97, 1.27] 1.97 [-1.97, 2.97] 1.97 [-1.97,	Mean Difference IV. Fixed, 85% CI Mean Difference IV. Fixed, 85% CI Mean Difference IV. Fixed, 85% CI Mean Difference IV. Fixed, 85% CI Mean Difference IV. Randem, 95% CI Mean Difference IV. Randem, 95% CI			

**Fig 4. The efficacy assessment of early treatment for Class III malocclusion versus late treatment.** The comparison was performed using five indices. 1: Angle SNA. The FM treatment group presented a greater increase in SNA than the controls (SMD = 1.09, 95% Cl = -0.70-2.88, P = 0.23). 2: Angle SNB. The FM treatment group presented a greater decrease in SNB than the untreated controls (SMD = -1.42, 95% Cl = -1.95--0.90, P < 0.00001). 3: Angle ANB. The FM treatment group presented a greater increase in ANB than the controls (SMD = 1.72, 95% Cl = -0.76-4.19, P = 0.17). 4: ANS-Me length. There were no significant differences in ANS-Me length between the early treatment group and the late treatment group (SMD = 0.50, 95% Cl = -1.87-2.86, P = 0.68). 5: SN/GoGn angle. There were no significant differences in SN/GoGn angle between the early treatment group (SMD = 0.5, 95% Cl = -0.14-1.14, P = 0.13). 6: Co-Gn length. There were no significant differences in Co-Gn length between the early treatment group and the late treatment group and the late treatment group and the late treatment group for the two treatment group (SMD = 2.94, 95% Cl = -3.78-9.74, P = 0.4). The maxillary protraction effect of the two treatment groups was similar.

doi:10.1371/journal.pone.0130096.g004

changes in the SNA (MD = 1.75, 95% CI = 1.53–1.97, P < 0.00001); SNB (MD = -1.54, 95% CI = -2.29–-0.80, P < 0.0001); ANB (MD = 3.51, 95% CI = 2.99–4.03, P < 0.00001); and SN/ GoGn (MD = 1.44, 95% CI = 0.21–2.68, P = 0.02). In addition, the FM/RME treatment group still exhibited effective improvements compared with the control group: SNA (MD = 1.38, 95% CI = 0.75–2.01, P < 0.0001); SNB (MD = -2.70, 95% CI = -3.34–-2.05, P < 0.00001); ANB (MD = 3.12, 95% CI = 1.43–4.81, P = 0.0003); and ANS-Me (MD = 1.43, 95% CI = -2.72–5.58, P = 0.50). The conclusions from the sensitivity analysis were the same as from the previous

Sensitivity analysis of FM group

1 SNA											
		FM			Contro	1		Mean Difference		Mean Difference	
Study or Subgroup	Mea	n S	D Tota	al Mear	n SD	Tota	I Weigh	IV, Fixed, 95% CI		IV, Fixed, 95% CI	
Chen 2012	2.2	5 1.8	1 2	2 0.2	1 1	17	5.9%	2.04 [1.15, 2.93]			
Gencer 2014	1.	9 0.3	4 1	5 0.:	2 0.3	15	5 90.2%	1.70 [1.47, 1.93]			
Ucem 2004	2.	8 1.7	6 1	4 0.3	3 1.16	14	3.9%	2.50 [1.40, 3.60]			
Total (95% CI)			5	1		46	5 100.0%	1.75 [1.53, 1.97]		•	
Heterogeneity: Chi <sup>2</sup>	= 2.36, 0	if = 2 (	P = 0.3	1); I <sup>2</sup> = 1	15%				10		10
Test for overall effect	t: Z = 15	.75 (P	< 0.00	001)					-10	-5 U 5 FM Control	10
2 SNB											
		FM		(	Control			Mean Difference		Mean Difference	
Study or Subgroup	Mear	SE	) Tota	I Mean	SD	Total	Weight	IV, Random, 95%	CI	IV. Random, 95% CI	
Chen 2012	-1.18	3 1.94	1 22	0.88	1.25	17	26.5%	-2.06 [-3.07, -1.05	5]	-	
Gencer 2014	-1.1	0.33	3 15	5 0.7	0.32	15	48.5%	-1.80 [-2.03, -1.57	ń	•	
Ucem 2004	-0.3	2 1.91	14	0.3	0.71	14	25.0%	-0.50 [-1.57, 0.57	ń.		
Total (95% CI)			51	l		46	100.0%	-1.54 [-2.29, -0.80	1	•	
Heterogeneity: Tau <sup>2</sup>	= 0.29; 0	chi² = {	5.81, df	= 2 (P =	= 0.05);	l² = 68	5%		-10	-5 0 5	10
Test for overall effect	: Z = 4.0	5 (P <	0.0001	)					-10	EM Control	10
3 ANB											
								Maan Difference		Maran Differences	
Chudu or Cubaroun	Maan	-m	Tetal	Maan	6D 3	Tetal	Moight	Wear Difference		W Bandam 05% Cl	
Chan 2012	2.40	1 15	10(a)	0.65	0.72	17	24 40/	1V. Ranuom, 95% C		IV. Kandom, 95% CI	
Chen 2012	3.42	1.15	45	-0.65	0.75	45	31.170	4.07 [3.46, 4.66]			
Gencer 2014	2.9	1.20	15	-0.5	1.00	14	49.0%	3.40 [3.22, 3.36]			
Ucem 2004	3	1.30	14	0.1	1.09	14	19.9%	2.90 [1.96, 3.62]			
Total (95% CI)			51			46	100.0%	3 51 [2 99 4 03]		•	
Hotorogonoity: Tau? -	0 14. CH	2 - 5	es df -	2 (P - 1	0.05) 18	- 669		0.01 [2.00, 4.00]	H		
Test for overall effect:	7 = 13.1	7 (P <	0,000	1)	0.00), 1	- 007	0		-10	-5 0 5	10
rest for overall effect.	L - 10.1	. (	0.0000	.,						FM Control	
4881/0-0-											
4 51N/ GoGn											
		M		Co	ntrol			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD T	otal V	Veight	IV, Random, 95% CI		IV, Random, 95% CI	
Chen 2012	2.46	1.75	22	-0.58	2.45	17	28.6%	3.04 [1.66, 4.42]			
Gencer 2014	0.8	0.38	15	-0.2 0	0.34	15	43.4%	1.00 [0.74, 1.26]			
Ucem 2004	0.6	2.54	14	0.1 0	0.94	14	28.0%	0.50 [-0.92, 1.92]			
Total (95% CI)			51			46 1	00.0%	1 44 [0 21 2 68]		•	
							00.070	1144 [0181, 8100]			
Heterogeneity: Tau <sup>2</sup> = 0	.90; Chi	<sup>2</sup> = 8.7	7, df =	2 (P = 0	.01); l²	= 77%	00.070	1.11 [0.2.1, 2.00]	10		

**Fig 5. Sensitivity analysis.** In the FM group, we chose 3 relatively high-quality studies (score  $\geq$ 4) to carry out the sensitivity analysis. 1: Angle SNA. The FM treatment group presented a greater increase in SNA than the controls (MD = 1.75, 95% CI = 1.53–1.97, P < 0.00001). 2: Angle SNB. The FM treatment group presented a greater decrease in SNB than the untreated controls (MD = -1.54, 95% CI = -2.29–0.80, P < 0.0001). 3: Angle ANB. The FM treatment group presented a greater increase in ANB than the controls (MD = 3.51, 95% CI = 2.99–4.03, P < 0.00001). 4: Angle SN/GoGn. The FM treatment group presented a greater increase in SN/GoGn than the controls (MD = 1.44, 95% CI = 0.21–2.68, P = 0.02). The sensitivity analysis results were consistent with previous results.

doi:10.1371/journal.pone.0130096.g005

results, suggesting that FM and FM/RME may be effective early treatments for maxillary dysplasia Class III malocclusion.

#### 6 Publication bias

A funnel plot was used to assess the publication bias of the literature. Symmetrical graphical funnel plots were obtained in all included studies (Fig 7).

#### Discussion

Treating Class III malocclusion is currently considered one of the most challenging and complex parts of orthodontic practice. According to some surveys, the prevalence of Class III malocclusion is as high as 14% in Asian populations and approximately 1% to 5% in white populations[<u>38–41</u>]. The main causes of skeletal Class III malocclusion are mandibular prognathism or macrognathia, maxillary retrognathism or micrognathia, or a combination of these features. It should be noted that it is far more common to encounter a retruded maxilla than a protruded mandible in skeletal Class III malocclusion[<u>42</u>]. In these cases, orthodontic treatment is needed to protract the maxilla and promote its growth instead of simply limiting mandibular growth to correct the skeletal discrepancy. As a result, the FM is widely used as a feasible and effective maxillary protractor via anterior displacement of the maxilla and

1 SNA											
	F	M/RME			ontrol	-		Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Iotal	Mean	SD	Tota	weight	IV, Fixed, 95% Cl		IV, Fixed, 95% CI	
Masucci 2011	1.9	2.9	22	1.5	1.8	16	17.8%	0.40 [-1.10, 1.90]		<b></b>	
Sar 2011	1.83	1.33	15	0.26	0.53	15	76.3%	1.57 [0.85, 2.29]			
YUKSEI 2001	1.9	4.06	17	0	3.68	1/	5.9%	1.90 [-0.70, 4.50]			
Total (95% CI)			54			48	100.0%	1.38 [0.75, 2.01]		•	
Heterogeneity: Chi <sup>2</sup> =	2.06, df	= 2 (P	= 0.36	); I <sup>2</sup> = 3	%				-10	-5 0 5	10
Test for overall effect	: Z = 4.28	8 (P < 0	0.0001	)					10	FM/RME Control	10
2 CNIP											
2 3IND											
	FN	/RME		С	ontrol			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Fixed, 95% C		IV, Fixed, 95% CI	
Masucci 2011	2	3.1	22	3.6	2.3	16	14.0%	-1.60 [-3.32, 0.12]		_	
Sar 2011	-2.3	1.23	15	0.65	0.65	15	83.1%	-2.95 [-3.65, -2.25]			
Yuksel 2001	-0.4	4.93	17	0.3	6.24	17	2.9%	-0.70 [-4.48, 3.08]			
Total (95% CI)			54			48	100.0%	-2.70 [-3.342.05]		•	
Heterogeneity: Chi <sup>2</sup> =	3.14 df :	= 2 (P :	= 0 21)	· 12 = 36	\$%				H		
Test for overall effect:	7 = 8 23	(P < 0	00001	)					-10	-5 0 5	10
root for overall endot.	2 0.20	(1 . 0		·						FM/RME Control	
3 ANB											
	EM	DME		60	ntrol			Moon Difforence		Moon Difforonco	
Study or Subgroup	Mean	SD 1	Cotal I	Maan	SD 1	[otal	Weight	IV Random 95% (	1	IV Random 95% Cl	
Maguagi 2011	nicun 0	1.4	22	2.1	1.6	10	25.0%	2 10 11 12 2 00			
Sar 2011	42 .	1.4	15	-2.1	0.71	15	35.9%	4 59 12 52 5 62			
Sal 2011 Vukcol 2001	9.2	27	17	0.30	2.2	17	20.0%	2 60 10 01 4 20			
1083012001	2.0	4.1		-0.0	2.0		20.070	2.00 [0.01, 4.20]			
Total (95% CI)			54			48	100.0%	3.12 [1.43, 4.81]		•	
Heterogeneity: Tau <sup>2</sup> = 1	1.82; Chi <sup>2</sup>	= 11.8	39. df =	2 (P =	0.003)	: I <sup>2</sup> = 8	3%		-		
Test for overall effect: 2	2 = 3.62 (	P = 0.0	0003)						-10	-5 0 5	10
										FINI/RIVE CONTO	
4 ANS-Me											
	FM/R	ME		Con	trol			Mean Difference		Mean Difference	
Study or Subgroup	Mean S	SD To	otal M	ean	SD To	otal V	Veight I	V. Random, 95% CI		IV. Random, 95% CI	
Masucci 2011	6.5 2	2.3	22	8.2 3	3.8	16	35.3%	-1.70 [-3.80, 0.40]			
Sar 2011	3.96 1.	74	15	0.1 0.	91	15	37.9%	3.86 [2.87, 4.85]		-	
Yuksel 2001	3.1 7.	85	17	1 5.	13	17	26.8%	2.10 [-2.36, 6.56]			
T-1-1/05% OB							00.00/				
Total (95% CI)			54			48 1	00.0%	1.43 [-2.72, 5.58]			_
Heterogeneity: Tau <sup>2</sup> = 11	.57; Chi <sup>2</sup>	= 22.1	18, df =	2 (P <	0.0001	); I <sup>2</sup> =	91%		-10	-5 0 5	10
Test for overall effect: Z	= 0.67 (P	= 0.50	))							FM/RME Control	

**Fig 6. Sensitivity analysis.** The same method was used in the FM/RME group; we also chose 3 relatively high-quality studies (score  $\geq$  4) to carry out the sensitivity analysis. The comparison was performed using five indices. 1: Angle SNA: The FM/RME treatment group presented a greater increase in SNA than the controls (MD = 1.38, 95% CI = 0.75–2.01, P < 0.0001). 2: Angle SNB. The FM/RME treatment group presented a greater increase in SNA than the controls (MD = 1.38, 95% CI = 0.75–2.01, P < 0.0001). 2: Angle SNB. The FM/RME treatment group presented a greater decrease in SNB than the untreated controls (MD = -2.70, 95% CI = -3.34–-2.05, P < 0.00001). 3: Angle ANB. The FM/RME treatment group presented a greater increase in ANB than the controls (MD = 3.12, 95% CI = 1.43–4.81, P = 0.0003). 4: ANS-Me length. There were no significant differences in ANS-Me length between the FM/RME treatment group and untreated controls (MD = 1.43, 95% CI = -2.72–5.58, P = 0.50). The sensitivity analysis result was consistent with previous results.

doi:10.1371/journal.pone.0130096.g006

Sensitivity analysis of FM + RME group

redirection of the mandibular position. A review of the literature offers theoretical support for clinical applications, and shows that using the maxillary protraction appliance results in a favorable change in the skeletal relationship when correcting Class III malocclusions [43-48]. From another perspective, several animal studies have shown histological changes of the circumaxillary sutures during anterior displacement [49-52].

If we want to gather adequate evidence to guide clinical practice and establish a standard of treatment, one approach is to treat patients with similar symptoms with the same treatment protocols. However, we cannot deny that definitive conclusions from any one trial are limited and should be treated casually, especially when they are based on studies with limited sample sizes [53,54]. Conversely, meta-analysis provides a reliable technique that can equate and compare research data from several independent, diverse research sources on a specific topic [55-58]. Therefore, a meta-analysis of the relevant literature was performed to determine whether there was support for a consensus viewpoint concerning the efficacy of FM therapy with or without rapid maxillary expansion, as well as the influence of age, treating Class III malocclusion. For the present meta-analysis and after strict elimination of the substandard studies, we only selected 12 independent studies that included a treatment group and naturally growing, untreated Class III controls. To reflect the real effects of FM, the controls are all untreated



Fig 7. Graphical funnel plots of the included studies. These symmetrical plots indicate the absence of publication bias in the present meta-analysis.

doi:10.1371/journal.pone.0130096.g007

Class III malocclusion patients rather than individuals without dental malocclusion. There is always disagreement regarding the optimal timing for orthopedic treatment. Many studies have supported early treatment to maximize maxillary anterior advancement, holding the optimion that early FM and expansion therapy is more efficient with early treatment time[<u>37</u>, <u>59–62</u>]. However, other investigators have held the opposite opinion that there is no relationship between the effect of maxillary FM protraction and treatment timing during pubertal growth[<u>59</u>, <u>63–66</u>]. This meta-analysis aims to determine if early FM protraction offers any benefit to Class III malocclusion patients over late treatment. It is important that this result be used as evidence to guide clinical practice and to avoid missing cases that can be compensated.

Overall, our meta-analysis aimed to explain three things: firstly, whether the maxilla FM protractor is an effective treatment for skeletal Class III malocclusion; secondly, whether FM protractor and maxilla expansion causes forward displacement of the maxilla and the inhibition of mandibular growth; and thirdly, whether an early treatment group benefits more from maxilla protractor devices than does a parallel late treatment group. The results are as follows: for the first issue, a summary of the meta-analysis suggests that a maxillary protraction appliance is effective for correcting anterior crossbite with a retruded maxilla. The changes in SNA and ANB in the FM group with regard to anterior movement of the maxilla indicate similarity with findings reported in the previous literature [67-70]. The anterior forward rotation of the maxilla was significant in the FM group (P < 0.00001), whereas no significant change was observed in the control group. The skeletal point A forward changes revealed that maxillary growth was achieved in the FM treatment group and that the FM protractor effectively facilitated skeletal growth of the maxilla. The negative change in SNB in the FM group indicates similar results. The negative numerical value change in SNB indicates that mandible growth is limited and that the forward change at the B point is controlled. The effects on combination of SN/GoGn and Me-ANS of the mandibular changes by a maxillary protractor reflect the clockwise rotation of the mandible, which has also been reported in several studies [45, 46, 48, 59, 71]. These results suggest that FM therapy causes the maxilla to be displaced anteriorly, whereas the mandible is rotated posteriorly. The increases of angle SNB (P < 0.00001) and the reduced facial height ANS-Me (P < 0.00001) offer the best evidence supporting this point. Although backward rotation of the mandible plane is an undesired effect of conventional FM therapy, it is inevitable, occurring both in the treatment group and in the Class III untreated subjects. Because the chin serves as the anchorage region in the FM protraction device, a clockwise rotation force was applied directly to the mandible, causing it to be displaced downward and backward during treatment and resulting in an increased mandibular plane angle and reduced facial height. Furthermore, the anterior rotation of the maxilla and growth of the mandible may also contribute to this phenomenon, and a longer treatment time may be another reason. However, we concluded that maxillary protraction FM therapy is an effective early clinical treatment method for skeletal Class III malocclusion. Another question that could arise is how to determine the optimal force characteristics regarding magnitude, duration, and direction to achieve the most effective clinical outcome. One systematic review provided the best clinical evidence. After careful classification and analysis, Yepes et al found that, indeed, no scientific evidence could allow for the definition of adequate parameters for force magnitude, direction, or duration of maxillary protraction FM treatment in Class III patients. However, by clinical consensus, to achieve more efficient treatment effects, they suggested that FMs should be used with 300-400 g of force per side for 14-16 hours per day by applying a force 20 mm greater than the maxillary occlusal plane [72]. According to the research of McNamara and Turley, the RME may disrupt the maxillary sutural system and could be combined with the FM to react as a whole unit [73, 74]. Could the FM applied with rapid maxillary expansion still work in correcting Class III patients, or do the two therapies interrupt each other? We have

performed the current analysis to address this question. The outcome of FM/RME is similar to that of FM, indicating that FM/RME is also an effective method to correct skeletal Class III malocclusion. However, the P value of ANS-Me was an exception to this conclusion, which may be attributed to the fact that the treatment group and untreated controls are still developing teenagers, and their changes in growth are therefore not stable. Furthermore, the amount of mandibular skeletal growth is not in equilibrium according to the chronological sequence. Consequently, we are expecting more articles related to our meta-analysis to be published, and we are very interested in exploring the final results.

The results of the last group suggest that early treatment was not more effective than was late FM therapy. An early treatment time involves the early mixed dentition period with the chronologic ages ranging from 7 to 10 years old, whereas a late treatment time is usually applied during late mixed dentition and early permanent teeth dentition from 11 to 14 years old. Evaluation of lateral cephalograms revealed no significant difference between the early treatment group and the late treatment group. In another words, the assumption that orthopedic forces on the maxilla and the mandible were more effective and advantageous during early treatment compared with later treatment was not supported (P > 0.05). The statistical findings offer the best evidence to address the third question. However, with the exception of the p value of SNB (P < 0.05), there is not enough evidence to represent the various angular changes in SNB between the two groups. Considering that the FM therapy patients are all either prepubertal or in puberty, it is expected that the natural growth of the mandible will result in the forward movement of point B and a natural change in SNB. In addition, younger children are expected to have more growth potential than do older children and a more significant change in SNB. As a result, our meta-analysis has provided the best evidence that early treatment is not more effective than late FM therapy. Although there were no differences in treatment time or clinical treatment effects between the early and late groups, the two groups were not entirely the same. In the early treatment patients, the maxillary sutures were still not fully fused at the chronologic ages of 7 to 10 years old. Therefore, the maxillary expansion and protraction effects still included some true skeletal decompensation with new bone deposition at the maxillary sutures. In other cases, the maxillary sutures completely closed after ten years of age. After closure of the maxillary sutures, the expansion of the maxilla lay in the eruption of the maxillary molar teeth and new bone deposition in the buccal side. Therefore, in the late treatment group, dental compensation played the leading role. This finding reminded us that true skeletal decompensation and maxilla expansion are considered possible only in younger children before maxillary suture closure. Although we found that that early treatment was not more effective than late FM therapy, we must admit that orthodontic interference only improves the clinical symptom with dental compensation rather than offering true skeletal decompensation after suture closure of the maxilla. True skeletal decompensation, which is considered possible in younger children, allows for good clinical stability, whereas dental compensation in older children is prone to relapse following appliance removal.

Nonetheless, this study has certain shortcomings similar to other articles due to the nature of meta-analysis. First, the numbers of relevant research articles and patients were not sufficiently large. In addition, some of the relevant studies were excluded from our analysis because of incomplete or overlapping data; consequently, our analysis may not provide a sufficient number of patients/cases. Moreover, not all sources of heterogeneity in the included studies could be addressed. Furthermore, certain methodological limitations exist because a meta-analysis is a retrospective study. Ultimately, we only provide evidence for the effectiveness of FM and FM/RME treatment using untreated controls. What we are also interested in is the difference between the FM- and FM/RME-treated groups. However, the newest relevant and eligible studies of FM groups and FM/RME controls are still not sufficient for conducting a meta-

analysis. Given these results, additional research in this field is necessary, and our metaanalyses will continually improve.

#### Conclusion

In conclusion, the data of our meta-analysis supported that FM and FM/RME treatment are both effective clinical early treatment methods for skeletal Class III malocclusion. The statistical analysis thoroughly proved that late FM therapy could achieve relatively similar outcomes to early treatment therapy. Although real skeletal development is much better than dental compensation, we cannot abandon maxillary expansion and protraction treatment for early permanent dentition, which we treated as the late group. Current evidence of correlative research still needs to be greatly expanded due to the limited number of published articles in this field. Therefore, we still wish to conduct a large, detailed, randomized, well-designed, comprehensive, controlled trial with a long follow-up visit to confirm our recent research.

#### **Supporting Information**

**S1** File. The list of full-text excluded articles with the reasons for exclusion. (DOC)

**S2 File. Checklist.** (DOC)

#### **Author Contributions**

Conceived and designed the experiments: WZ YZ. Performed the experiments: WZ HCQ. Analyzed the data: MY YZ. Contributed reagents/materials/analysis tools: HCQ. Wrote the paper: WZ HCQ.

#### References

- 1. Ellis EE, McNamara JA Jr (1984) Components of adult Class III malocclusion. Am J Orthod 85: 277–290.
- Nanda R (1980) Biomechanical and clinical considerations of a modified protraction headgear. Am J Orthod 78: 125–139. PMID: 6931484
- Sanborn RT (1955) Differences between the facial skeletal patterns of Class III malocclusion and normal occlusion. Angle Orthod 25: 208–222.
- 4. McNamara JA, Brudon WL (1993) Orthodontic and orthopedic treatment in the mixed dentition. Ann Arbor, Mich: Needham Press p: 285–293.
- Guyer EC, Ellis EE, McNamara JA Jr, Behrents RG (1986) Components of Class III malocclusion in juveniles and adolescents. Angle Orthod 56: 7–30. PMID: <u>3485393</u>
- Ellis E III, McNamara JA Jr (1984) Components of adult Class III malocclusion. J Oral Maxillofac Surg 42:295–305. PMID: 6585502
- Delaire J, Verdon P, Lumineau JP, Cherga-Négréa A, Talmant J, Boisson M (1972) Some results of extra-oral tractions with front-chin rest in the orthodontic treatment of class IIII maxillomandibular malformations and of bony sequelae of cleft lip and palate. Rev Stomatol Chir Maxillofac 73: 633–642. PMID: <u>4514929</u>
- Roberts CA, Subtelny JD (1988) An American Board of Orthodontics case report: Use of the face mask in the treatment of maxillary skeletal retrusion. Am J Orthod Dentofacial Orthop 93: 388–394. PMID: 3284331
- Kim JH, Viana MA, Graber TM, Omerza FF, BeGole EA (1999) The effectiveness of protraction facemask therapy: a meta-analysis. Am J Orthod Dentofacial Orthop 115: 675–685. PMID: <u>10358251</u>
- Mandall N, DiBiase A, Littlewood S, Nute S, Stivaros N, McDowall R, et al. (2010) Is early Class III protraction facemask treatment effective? A multicentre, randomized, controlled trial: 15-month follow-up. J Orthod 37: 149–161. doi: 10.1179/14653121043056 PMID: 20805344

- Showkatbakhsh R, Jamilian A (2010) A novel approach in treatment of maxillary deficiency by reverse chin cup. Int J Orthod Milwaukee 21: 27–31. PMID: <u>20687313</u>
- Kokich VG, Shapiro PA, Oswald R, Koskinen-Moffett L, Clarren SK (1985) Ankylosed teeth as abutments for maxillary protraction: a case report. Am J Orthod 88: 303–307. PMID: <u>3901773</u>
- Singer SL, Henry PJ, Rosenberg I (2000) Osseo integrated implants as an adjunct to facemask therapy: a case report. Angle Orthod 70: 253–262. PMID: <u>10926436</u>
- Jamilian A, Showkatbakhsh R (2010) Treatment of maxillary deficiency by mini screw implants-a case report. J Orthod 37: 56–61. doi: <u>10.1179/14653121042876</u> PMID: <u>20439927</u>
- Jamilian A, Haraji A, Showkatbakhsh R, Valaee N (2011) The effects of miniscrew with class III traction in growing patients with maxillary deficiency. Int J Orthod Milwaukee 22: 25–30. PMID: <u>22031991</u>
- De Clerck HJ, Cornelis MA, Cevidanes LH, Heymann GC, Tulloch CJ (2009) Orthopedic traction of the maxilla with mini plates: a new perspective for treatment of midface deficiency. J Oral Maxillofac Surg 67: 2123–2129. doi: 10.1016/j.joms.2009.03.007 PMID: 19761906
- Baccetti T, de Clerck HJ, Cevidanes LH, Franchi L (2011) Morphometric analysis of treatment effects of bone-anchored maxillary protraction in growing Class IIIpatients. Eur J Orthod 33: 121–125. doi: <u>10.</u> <u>1093/ejo/cjq170</u> PMID: <u>21187527</u>
- Showkatbakhsh R, Jamilian A, Behnaz M (2011) Treatment of maxillary deficiency by mini plates: a case report. ISRN Surg 2011: 854924. doi: <u>10.5402/2011/854924</u> PMID: <u>22084781</u>
- Cevidanes L, Baccetti T, Franchi L, McNamara JA, de Clerck H (2010) Comparison of two protocols for maxillary protraction: bone anchors versus face mask with rapid maxillary expansion. Angle Orthod 80: 799–806. doi: 10.2319/111709-651.1 PMID: 20578848
- Jager A, Braumann B, Kim C, Wahner S (2001) Skeletal and dental effects of maxillary protraction in patients with angle class III malocclusion: A meta-analysis. J Orofac Orthop 62: 275–284. PMID: <u>11508104</u>
- Toffol LD, Pavoni C, Baccetti T, Franchi L, Cozza P (2008) Orthopedic treatment outcomes in Class III malocclusion. A systematic review. Angle Orthod 78: 561–573. doi: <u>10.2319/030207-108.1</u> PMID: <u>18416617</u>
- Baccetti T, Franchi L (2011) Prediction of the outcome of orthodontic treatment of Class III malocclusion. Eur J Orthod 33: 332. doi: <u>10.1093/ejo/cjr066</u> PMID: <u>21616981</u>
- Arman A, Toygar TU, Abuhijleh E (2004) Profile changes associated with different orthopedic treatment approaches in Class III malocclusions. Angle Orthod 74: 733–740. PMID: <u>15673133</u>
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 18: 800–804. PMID: <u>18049194</u>
- Murphy GK, McAlister FA, Weir DL, Tjosvold L, Eurich DT (2014) Cardiovascular medication utilization and adherence among adults living in rural and urban areas: a systematic review and meta-analysis. BMC Public Health 14: 544. doi: 10.1186/1471-2458-14-544 PMID: 24888355
- Kajiyama K, Murakami T, Suzuli A (2004) Comparison of orthodontic and orthopedic effects of a modified maxillary protractor between deciduous teeth and early mixed dentition. Am J Orthod Dentofacial Orthop 126: 23–32. PMID: <u>15224055</u>
- Sar C, Arman-Ozcirpici A, Uckan S, Yazici AC (2011) Comparative evaluation of maxillary protraction with or without skeletal anchorage. Am J Orthod Dentofacial Orthop 139: 636–649. doi: <u>10.1016/j.</u> ajodo.2009.06.039 PMID: 21536207
- Ucem TT, Uçüncü N, Yüksel S (2004) Comparison of double-plate appliance and facemask therapy in treating Class III malocclusions. Am J Orthod Dentofacial Orthop 126:672–9. PMID: <u>15592214</u>
- Gencer D, Kaygisiz E, Yuksel S, Tortop T (2014) Comparison of double-plate appliance/facemask combination and facemask therapy in treating Class III malocclusions. Angle Orthod.
- Kajiyama K, Murakami T, Suzuki A (2000) Evaluation of the modified maxillary protractor applied to Class III malocclusion with retruded maxilla in early mixed dentition. Am J Orthod Dentofacial Orthop 118:549–559. PMID: <u>11094369</u>
- Yuksel S, Ucem TT, Keykubat A (2001) Early and late facemask therapy. European Journal of Orthodontics 23: 559–568. PMID: <u>11668875</u>
- Franchi L, Baccetti T, McNamara JA (2004) Post-pubertal assessment of treatment timing for maxillary expansion and protraction therapy followed by fixed appliances. Am J Orthod Dentofacial Orthop 126:555–568. PMID: <u>15520688</u>
- Kilicoglu H, Dent M, Kirlic Y (1998) Profile changes in patients with Class III malocclusions after Delaire mask therapy. Am J Orthod Dentofacial Orthop 113:453–462. PMID: <u>9563362</u>

- Lee DY, Kim ES, Lim YK, Ahn SJ (2010) Skeletal changes of maxillary protraction without rapid maxillary expansion. Angle Orthod 80: 692–698.
- Masucci C, Franchi L, Defraia E, Mucedero M, Cozza P, Baccetti T (2011) Stability of rapid maxillary expansion and facemask therapy: A long-term controlled study. Am J Orthod Dentofacial Orthop 140: 493–500. doi: <u>10.1016/j.ajodo.2010.09.031</u> PMID: <u>21967936</u>
- Chen LL, Chen RJ, Yang YM, Ji GP, Shen G (2012) The effects of maxillary protraction and its longterm stability: a clinical trial in Chinese adolescents. European Journal of Orthodontics 34: 88–95. doi: <u>10.1093/ejo/cjq185</u> PMID: <u>21325335</u>
- Baccetti T, Franchi L, McNamara JA (2000) Treatment and post-treatment craniofacial changes after rapid maxillary expansion and facemask therapy. Am J Orthod Dentofacial Orthop 118:404–413. PMID: <u>11029736</u>
- Haynes S (1970) The prevalence of malocclusion in English school children aged 11–12 years. Trans Eur Orthod Soc: 89–98.
- Thilander B, Myberg N (1973) The pre-valence of malocclusion in Swedish school children. Scand J Dent Res 81: 12–20. PMID: <u>4510864</u>
- 40. Iwagaki H (1938) Hereditary influence of malocclusion. Am J OrthodOral Surg 24: 328–338.
- 41. Allwright WC, Burndred WH (1964) A survey of handicapping dento facial anomalies among Chinese in Hong Kong. Int Dent J 14: 505–519.
- Masaki F (1980) The longitudinal study of morphological differences in the cranial base and facial structure between Japanese and American white. J Jpn Orthod Soc 39: 436–456.
- Hata S, Itoh T, Nakagawa M, Kamogashira K, Ichikawa K, Matsumoto M, et al. (1987) Biomechanical effects of maxillary protraction on the craniofacial complex. Am J Orthod Dento facial Orthop 91: 305–311.
- Irie M, Nakamura S (1975) Orthopedic approach to severe skeletal Class III malocclusion. Am J Orthod 67: 377–392. PMID: <u>1092182</u>
- 45. Kajiyama K, Murakami T, Suzuki A (2000) Evaluation of the modified maxillary protractor applied to Class III malocclusion with retruded maxilla in early mixed dentition. Am J Orthod Dento facial Orthop 118: 549–559. PMID: 11094369
- Nartallo-Turley PE, Turley PK (1998) Cephalometric effects of combined palatal expansion and facemask therapy on Class III malocclusion. Angle Orthod 68: 217–224. PMID: 9622758
- Ngan P, Hägg U, Yiu CKY, Merwin D, Wei SHY (1996) Treatment response to maxillary expansion and protraction. Eur J Orthod 18:151–168. PMID: 8670927
- Ngan P, Hägg U, Yiu C, Merwin D, Wei SHY (1996) Soft tissue and dento skeletal profile changes associated with maxillary expansion and protraction headgear treatment. Am J Orthod Dento facial Orthop 109: 38–49. PMID: <u>8540481</u>
- Dellinger EL (1973) A preliminary study of anterior maxillary displacement. Am J Orthod 63: 509–516. PMID: 4633054
- Jackson GW, Kokich VG, Shapiro PA (1979) Experimental response to anteriorly directed extra-oral force in young Macaca nemestrina. Am J Orthod 75: 319–333.
- Kambara T (1977) Dento facial changes produced by extra-oral force in Macaca irus. Am J Orthod 71: 249–277. PMID: 402814
- **52.** Nanda R (1978) Protraction of maxilla in rhesus monkeys by controlled extra-oral forces. Am J Orthod 74:121–141. PMID: <u>99041</u>
- Lau J, Antman EM, Jimenez-Silva J (1992) Cumulative meta-analysis of therapeutic trials of myocardial infarction. N Engl J Med 327:248–54. PMID: <u>1614465</u>
- Roberts SA, Viana MA, Nazari J, Bauman JL (1994) Invasive and non-invasive methods to predict the long-term efficacy of amiodarone: a compilation of clinical observations using meta-analysis. Pacing Clin Electrophysiol 17: 1590–1601. PMID: <u>7800560</u>
- 55. Glass GV (1976) Primary, secondary and meta-analysis of research. Educ Researcher 5: 3–8.
- 56. Dawson-Saunders B, Trapp RG (1990) Basic and clinical biostatistics. Norwalk (CT): Appleton & Lange Co p. 222–224.
- Wolf FM (1986) Meta-analysis: quantitative methods for research synthesis. Newbury Park (CA): Sage.
- Cohen PA (1992) Meta-analysis: application to clinical dentistry and dental education. J Dent Educ 56:172–175. PMID: <u>1573085</u>
- Takada K, Petdachai S, Sakuda M (1993) Changes in dentofacial morphology in skeletal Class III children treated by a modified maxillary protraction headgear and a chin cup: a longitudinal cephalometric appraisal. European Journal of Orthodontics 15: 211–221. PMID: <u>8339762</u>

- Chong YH, Ive JC, Ártun J (1996) Changes following the use of protraction headgear for early correction of Class III malocclusion. Angle Orthodontist 66: 351–362. PMID: 8893105
- Shanker S, Ngan P, Wade D, Beck M, Yiu C, Hägg U, et al. (1996) Cephalometric A-point changes during and after maxillary protraction and expansion. American Journal of Orthodontics and Dento facial Orthopedics 110: 423–430.
- Kapust AJ, Sinclair PM, Turley PK (1998) Cephalometric effects of facemask/expansion therapy in Class III children: a comparison of three age groups. American Journal of Orthodontics and Dentofacial Orthopedics 113: 204–212. PMID: <u>9484212</u>
- Baik HS (1995) Clinical results of the maxillary protraction in Korean children. American Journal of Orthodontics and Dentofacial Orthopedics 108: 583–592. PMID: 7503035
- 64. Merwin D, Ngan P, Hagg U, Yiu C, Wei SH (1997) Timing for effective application of anteriorly directed orthopedic force to the maxilla. Am J Orthod Dentofacial Orthop 112:292–9. PMID: <u>9294359</u>
- Sung S J, Baik H S (1998) Assessment of skeletal and dental changes by maxillary protraction. American Journal of Orthodontics and Dentofacial Orthopedics 114: 492–502. PMID: <u>9810044</u>
- 66. Cha K S (2003) Skeletal changes of maxillary protraction in patients exhibiting skeletal Class III malocclusion: a comparison of three skeletal maturation groups. Angle Orthodontist 73: 26–35. PMID: 12607852
- Gallagher RW, Miranda F, Buschang PH (1998) Maxillary protraction: treatment and posttreatment effects. Am J Orthod Dentofacial Orthop 113: 612–619. PMID: <u>9637563</u>
- Pangrazio-Kulbersh V, Berger J, Kersten G (1998) Effects of protraction mechanics on the midface. Am J Orthod Dentofacial Orthop 114:484–491. PMID: 9810043
- Saadia M, Torres E (2000) Sagittal changes after maxillary protraction with expansion in Class III patients in the primary, mixed, and late mixed dentitions: a longitudinal retrospective study. Am J Orthod Dentofacial Orthop 117: 669–680. PMID: 10842110
- Suda N, Ishii-Suzuki M, Hirose K, Hiyama S, Suzuki S, et al. (2000) Effective treatment plan for maxillary protraction: is the bone age useful to determine the treatment plan? Am J Orthod Dentofacial Orthop 118:55–62. PMID: 10893473
- Filho OGS, Magro AC, Filho LC (1998) Early treatment of the Class III malocclusion with rapid maxillary expansion and maxillary protraction. Am J Orthod Dentofacial Orthop 113: 196–203. PMID: <u>9484211</u>
- Yepes E, Quintero P, Rueda ZV, Pedroza A (2014) Optimal force for maxillary protraction facemask therapy in the early treatment of class III malocclusion. European Journal of Orthodontics 36: 586–594. doi: 10.1093/ejo/cjt091 PMID: 24351569
- McNamara JA Jr (1987) An orthopedic approach to the treatment of Class III malocclusion in young patients. J Clin Orthod. 21: 598–608. PMID: 3328750
- 74. Turley PK (1988) Orthopedic correction of Class III malocclusion with palatal expansion and custom protraction headgear. J Clin Orthod. 23: 314–325.